Arcutis Biotherapeutics, Inc.
ARQT
$22.91
$0.673.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 88.47% | 77.33% | 53.07% | 40.34% | 46.58% |
| Total Depreciation and Amortization | 138.23% | 117.48% | 346.90% | 212.20% | 28.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.79% | 6.33% | 3.68% | 10.25% | 10.63% |
| Change in Net Operating Assets | -130.96% | -160.04% | 2.97% | -37.06% | 35.83% |
| Cash from Operations | 94.98% | 80.58% | 62.99% | 44.06% | 54.60% |
| Capital Expenditure | -379.72% | -360.40% | -1,084.29% | -117.05% | 66.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -202.09% | 157.99% | 239.34% | 58.66% | -83.97% |
| Cash from Investing | -204.97% | 156.86% | 238.48% | 58.20% | -84.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.80% | -97.78% | -98.19% | -98.16% | 64.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -89.47% | -135.82% | -136.16% | -136.19% | -34.66% |
| Foreign Exchange rate Adjustments | 171.49% | -286.57% | 164.15% | -122.54% | -370.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -65.43% | -425.21% | 44.03% | -226.40% | -150.43% |